BiomX Inc. (NYSE American: PHGE) is a clinical-stage biopharmaceutical company focused on phage therapy, developing bacteriophage-based treatments targeting bacterial infections. The company operates through its wholly owned subsidiary Adaptive Phage Therapeutics LLC (APT). BiomX generates no product revenue as of the 10-K filed 2026-02-19, relying instead on external financing to fund research and development activities. As of late 2025 and early 2026, the company faced material operational disruption: its Israeli subsidiary, BiomX Ltd., filed for insolvency in Israel on December 16, 2025, and the District Court of Tel-Aviv appointed a trustee on January 25, 2026 to administer the wind-down. BiomX no longer controls BiomX Ltd. and no longer consolidates its assets. The company entered a Securities Purchase Agreement with Pyu Pyu Capital, LLC in December 2025, with closing completed January 13, 2026, as a financing mechanism. The business is pre-revenue, capital-dependent, and operating under significant financial stress as disclosed in the FY2025 annual filing.

Revenue model

No product revenue disclosed in the 10-K filed 2026-02-19. The company funds operations through equity and debt financings, including a Securities Purchase Agreement with Pyu Pyu Capital, LLC closed January 13, 2026.

Products and services

Bacteriophage-based therapeutics for bacterial infections, developed through wholly owned subsidiary Adaptive Phage Therapeutics LLC (APT). No approved or commercialized products disclosed in the filing.

Customers and end markets

No commercial customers disclosed. End market is bacterial infectious disease treatment, targeting patients with drug-resistant or difficult-to-treat bacterial infections.

Value-chain role

Clinical-stage drug developer; pre-commercial biopharmaceutical company engaged in research and development of phage-based therapeutic candidates.

Geographic exposure

U.S.-based operations via Adaptive Phage Therapeutics LLC. Israeli subsidiary BiomX Ltd. entered insolvency proceedings in Israel as of December 16, 2025 and is no longer consolidated as of the filing date.

Source: SEC 10-K, filed 2026-02-19

Industry: Biological Products, (No Diagnostic Substances) Peers: Pluri Inc Chemomab Therapeutics Ltd Galmed Pharmaceuticals Ltd Neurosense Therapeutics Ltd Scisparc Ltd Notable Labs, Ltd.